CA
NZ
UK
AU
IND
US
Illumina, Inc. reported strong second-quarter financial results with revenue hitting $1.16 billion, reflecting a year-over-year growth of 9.5%. This performance surpassed the expectations set by market analysts, who had consensus estimates for earnings per share (EPS). Strong demand for the company's NovaSeq X platform …
ImmunityBio, Inc. has obtained marketing authorization from the UAE for ANKTIVA, now approved for two critical cancer indications. This expansion signals a significant growth opportunity for investors, particularly as shares have surged 268.8% year-to-date.Key HighlightsImmunityBio's ANKTIVA gains marketing approval in the UAE, now available …
Evommune (NYSE: EVMN) has commenced its Phase 2b clinical trial for EVO756 to treat migraine, a move that comes as shares have dropped 34% year-to-date. Initiation of the trial represents a critical step in addressing the substantial unmet need in migraine therapies, appealing to …
EyePoint, Inc. has finished enrollment for 480 patients in its Phase 3 trials for DURAVYU, a potential treatment for diabetic macular edema. The rapid enrollment highlights the product's significance in addressing a major retinal disease market, with topline data expected in 2027.Key HighlightsEyePoint, Inc. …
Genprex, Inc. has been granted by Nasdaq an exception allowing it until December 7, 2026, to meet the $1.00 Minimum Bid Price requirement. This critical move aims to provide the company a chance to stabilize following an 84.6% year-to-date decline in its stock value.Key …
Ginkgo Bioworks Holdings, Inc. is set to review its business performance for the second quarter of 2026 on August 5, with a scheduled presentation that starts at 4:30 p.m. ET. This session marks a key moment for shareholders, providing insights into the company’s financial …
Glucotrack, Inc. (NASDAQ: GCTK) faces significant market pressure as its short position rises to 95% of shares outstanding, contributing to a 27.95% decline today. Investors should be cautious as the company's year-to-date performance reflects an overall 79.9% drop, indicating ongoing challenges.Key HighlightsThe company's market …
Disc Medicine, Inc. reported a second-quarter loss of $-1.54 per share on July 30, an improvement over the expected $-1.78. This update emphasizes the company's strategic advancement in its clinical pipeline, particularly concerning its lead drug, bitopertin.Key HighlightsDisc Medicine reported a second‑quarter net loss …
Dexcom Inc. (NASDAQ: DXCM) reported a strong 13% increase in revenue, totaling $1.308 billion for the latest quarter. This achievement surpasses analysts' expectations, which anticipated earnings of $0.62 per share, with Dexcom clocking in at $0.70 EPS. The results signify the company's growing market …
This loss stands out as a critical indicator of the ongoing pressures faced by the healthcare sector, particularly in community-based health solutions. Investors may perceive this dip as a potential red flag for the company's operational sustainability and ability to attract future investments, creating …
Please wait processing your request...